Pfizer settles last whistleblower suit for $14.5M; NJ offers $3.6M retraining for laid-off pharma workers;

> Pfizer ($PFE) agreed to pay $14.5 million to settle the last of 10 whistleblower lawsuits, wrapping up allegations that it marketed its Detrol drug for off-label use as a treatment for enlarged prostate and bladder obstruction. News

> The government of New Jersey said it would deliver $3.6 million in federal funding for retraining programs for laid-off pharma workers. Report

> Valeant Pharmaceuticals ($VRX) obtained $2 billion in new financing to refinance existing bridge loans and revolving debt. Item

> Bulgarian generics maker Sopharma plans to list its shares in Warsaw as well as on the Sofia bourse where they are now traded. Article

> Watson Pharmaceuticals ($WPI) won the FDA nod for a smaller-sized version of its testosterone patch Androderm. Story

> Janssen Therapeutics, a unit of Johnson & Johnson ($JNJ), got the FDA's blessing for a label update on its HIV drug Prezista to include positive data from a recent trial in treatment-naive patients. News

> Shanghai Modern Pharmaceutical plans to invest 277 million yuan ($43.4 million) to build a production base in Henan province. Article

> Actelion won its motion for a new trial in a licensing dispute with Asahi Kasei Pharma over the drug compound fasudil. Report

And Finally... Wal-Mart Stores won't offer health insurance to many part-time workers and will charge tobacco users more for their coverage. Story

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.